Summary of Study ST002179

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR001387. The data can be accessed directly via it's Project DOI: 10.21228/M8FB0C This work is supported by NIH grant, U2C- DK119886.


This study contains a large results data set and is not available in the mwTab file. It is only available for download via FTP as data file(s) here.

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST002179
Study TitleImpact of nitisinone on the cerebrospinal fluid metabolome of a murine model of alkaptonuria
Study SummaryBackground: Nitisinone induced hypertyrosinaemia is well documented in Alkaptonuria (AKU), and there is uncertainty over whether it may contribute to a decline in cognitive function and or mood by altering neurotransmitter metabolism. The aim of this work was to evaluate the impact of nitisinone on the cerebrospinal fluid (CSF) metabolome in a murine model of AKU, with a view to providing additional insight into metabolic changes that occur following treatment with nitisinone. Methods: 17 CSF samples were collected from BALB/c Hgd-/-mice (n=8, treated with nitisinone – 4 mg/L and n=9, no treatment). Samples were diluted 1:1 with deionised water and analysed using a 1290 Infinity II liquid chromatography system coupled to a 6550 quadrupole time-of-flight mass spectrometry (Agilent, Cheadle, UK). Raw data were processed using a targeted feature extraction algorithm and an established in-house accurate mass retention time database. Matched entities (±10 ppm theoretical accurate mass and ±0.3 minutes retention time window) were filtered based on their frequency and variability. Experimental groups were compared using a moderated t-test with Benjamini-Hochberg false-discovery rate adjustment. Results: Tyrosine, acetyl-tyrosine, γ-glutamyl-tyrosine, p-hydroxyphenylacetic acid and 3-(4-hydroxyphenyl)lactic acid were shown to increase in abundance (log2 fold change 2.6-6.9, 3/5 were significant p<0.05) in the mice that received nitisinone. Several other metabolites of interest were matched but no significant differences were observed, including the aromatic amino acids phenylalanine and tryptophan, and monoamine metabolites adrenaline, 3-methoxy-4-hydroxyphenylglycol and octopamine. Conclusions: Evaluation of the CSF metabolome of a murine model of AKU showed a significant difference in the abundance of a limited number of metabolites. None of these have been reported in CSF from a murine model of AKU previously. Moreover this study confirms that some monoamine metabolites do not appear to be altered following nitisinone therapy.
University of Liverpool Institute of Life Course & Medical Sciences
Last NameDavison
First NameAndrew
Address1. Department of Clinical Biochemistry and Metabolic Medicine, Liverpool Clinical Laboratories, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK; 2. Department of Musculoskeletal and Ageing Science, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, UK 3. School of Exercise Science, Liverpool John Moores University, Liverpool, UK
Phone0151 706 4011
Submit Date2022-05-13
Num Groups2
Total Subjects17
Raw Data AvailableYes
Raw Data File Type(s)d, mzML
Analysis Type DetailLC-MS
Release Date2022-06-08
Release Version1
Andrew Davison Andrew Davison application/zip

Select appropriate tab below to view additional metadata details:


Subject type: Mammal; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Treatment group
SA209243Hgd81.3 + Nitisinone POSNitisinone
SA209244Hgd81.2 + Nitisinone POSNitisinone
SA209245Hgd81.1 + Nitisinone POSNitisinone
SA209246Hgd82.1 + Nitisinone POSNitisinone
SA209247Hgd82.2 + Nitisinone POSNitisinone
SA209248Hgd83.2 - No treatment POSNitisinone
SA209249Hgd83.1 + Nitisinone POSNitisinone
SA209250Hgd81.1 + Nitisinone NEGNitisinone
SA209251Hgd80.2 + Nitisinone POSNitisinone
SA209252Hgd83.1 + Nitisinone NEGNitisinone
SA209253Hgd82.1 + Nitisinone NEGNitisinone
SA209254Hgd81.3 + Nitisinone NEGNitisinone
SA209255Hgd81.2 + Nitisinone NEGNitisinone
SA209256Hgd83.2 - No treatment NEGNitisinone
SA209257Hgd82.2 + Nitisinone NEGNitisinone
SA209258Hgd81.6 - No treatment POSNo Treatment (control)
SA209259Hgd81.5 - No treatment POSNo Treatment (control)
SA209260Hgd81.4 - No treatment POSNo Treatment (control)
SA209261Hgd82.3 - No treatment POSNo Treatment (control)
SA209262Hgd82.4 - No treatment POSNo Treatment (control)
SA209263Hgd81.6 - No treatment NEGNo Treatment (control)
SA209264Hgd83.4 - No treatment POSNo Treatment (control)
SA209265Hgd83.3 - No treatment POSNo Treatment (control)
SA209266Hgd80.4 - No treatment POSNo Treatment (control)
SA209267Hgd80.3 - No treatment POSNo Treatment (control)
SA209268Hgd83.4 - No treatment NEGNo Treatment (control)
SA209269Hgd80.3 - No treatment NEGNo Treatment (control)
SA209270Hgd80.4 - No treatment NEGNo Treatment (control)
SA209271Hgd83.3 - No treatment NEGNo Treatment (control)
SA209272Hgd81.5 - No treatment NEGNo Treatment (control)
SA209273Hgd82.3 - No treatment NEGNo Treatment (control)
SA209274Hgd82.4 - No treatment NEGNo Treatment (control)
SA209275Hgd81.4 - No treatment NEGNo Treatment (control)
Showing results 1 to 33 of 33